瘤抗原主导的树突细胞衍生外体与殖民地刺激因子-1受体抑制剂协同作用,通过调节瘤微环境和系统免疫力
Anjali Barnwal1,2, Vidit Gaur1,2, Anindita Sengupta1,2
1Centre for Biomedical Engineering, Indian Institute of Technology Delhi, New Delhi 110016, India.
ACS biomaterials science & engineering
|October 23, 2023
概括
成熟的树突细胞衍生外体 (mDexTA) 与CSF-1R抑制剂 (PLX-3397) 结合,通过增强T细胞透和调节瘤微环境,有效延缓瘤生长并改善黑色素瘤模型的存活率.
科学领域:
- 免疫学 免疫学 免疫学
- 癌症治疗 癌症治疗
- 异构体生物学 异构体生物学
背景情况:
- 树突细胞衍生外体 (Dex) 是有前途的,但由于树突细胞 (DC) 成熟不充分和免疫抑制瘤微环境 (TME),临床疗效面临挑战.
- 准CSF-1/CSF-1R通路可以耗尽TME内的免疫抑制细胞,如瘤相关巨细胞 (TAM) 和髓质衍生抑制细胞 (MDSC).
研究的目的:
- 研究成熟的Dex加载瘤抗原 (mDexTA) 与CSF-1R抑制剂 (PLX-3397) 结合用于增强抗瘤免疫力的疗效.
- 评估这种联合治疗对免疫细胞透,TME调节和临床前黑色素瘤模型的整体存活率的影响.
主要方法:
- 来自骨髓的DCs与成熟尾酒和瘤抗原进行培养,以产生mDexTA.
- 一种CSF-1R抑制剂PLX-3397在B16-F10小鼠黑色素瘤模型中与mDexTA结合使用.
- 分析了免疫细胞群 (CD8 T 细胞,TAM,MDSC,Th1/Th2) 和瘤生长.
主要成果:
- mDexTA表现出MHC和共刺激分子的增强表达,比不成熟的Dex更有效地激活天真的DC和T细胞.
- 与mDexTA单独治疗相比,mDexTA和PLX-3397的组合显著延迟了瘤生长和改善了生存率.
- 组合治疗促进了CD8T细胞的透,将Th1/Th2平衡转移到Th1,并在TME中耗尽了TAM和MDSC.
结论:
- mDexTA和PLX-3397的组合显示出协同作用的抗瘤作用,克服了单一治疗的局限性.
- 这种组合疗法是治疗包括黑色素瘤在内的固体瘤的有希望的策略,通过增强抗瘤免疫力和调节TME.
更多相关视频
07:20Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
Published on: January 14, 2011
14.8K
11:48Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes
Published on: May 31, 2018
11.5K
相关概念视频
Tumor Immunotherapy
538
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
538
Regulation of Hematopoietic Stem Cells
3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
